Sign up
Pharma Capital

Orthocell secures European market authorisation for medical device

CelGro device plays a critical role in dental bone and soft tissue regeneration.
a dental clinic
Addressable market of US$600+ million per annum

Orthocell Ltd (ASX:OCC) has received the European regulatory approval (CE Mark) for its CelGro collagen medical device.

CelGro, which is used for a range of dental bone and soft tissue regeneration procedures, can now be marketed and sold within the European Union (EU).

Significantly, the CE mark validates the potential of the entire technology platform by endorsing CelGro’s clinical performance and quality manufacturing.

CelGro is manufactured by Orthocell at its quality controlled Good Manufacturing Practices (GMP) licensed facility in Western Australia.

The company uses its proprietary SMRT tissue engineering process, developed in conjunction with
Professor Minghao Zheng and the University of Western Australia.

CelGro plays a critical role in dental bone and soft tissue regeneration therapy as it offers superior functionality over existing products for improved tissue repair.

CelGro’s dental addressable market is estimated to be worth more than US$600 million per annum, with circa 1.5 million procedures that utilise these types of scaffolds being completed each year.

A key advantage of CelGro over other scaffolds is that it integrates with the soft tissue under repair and also degrades at the same rate as the body heals.

The approval provides a strong foundation for the company to progress additional dental regulatory applications in key markets, such as the U.S., Japan and Australia.



Register here to be notified of future OCC Company articles
View full OCC profile

Orthocell Ltd Timeline

Newswire

Orthocell gets ready to raise

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.